To assess the effects of chemoimmunotherapy on post-chemotherapy cognitive impairments (PCCI) in patients with B-cell non-Hodgkin lymphoma (NHL), we used objective and subjective measures of cognitive functions in combination with serum parameters and neuroelectric recordings. Self-perceived status of cognition, fatigue and emotional functioning were reduced in patients (n=30) compared to healthy controls (n=10). Cognitive performance was impaired in patients with NHL compared to controls and a norm sample (n=1179). PCCI was more severe in patients treated with rituximab and bendamustine (BR) than in patients who received R in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) polychemotherapy (R-CHOP). Individual alpha peak frequency and serum brain-derived neurotrophic factor (BDNF) levels in patients with NHL correlated with accuracy in the objective cognition test. Higher serum interleukin-6 (IL-6) concentrations were associated with higher fatigue levels. Patients with NHL and especially those who were treated with BR were affected by PCCI. BDNF and IL-6 might be involved in the pathogenesis of PCCI and fatigue.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/10428194.2014.915546 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analysis of the positive influence of hyperbaric oxygen therapy on the prognosis and hearing control of patients with noise-induced hearing loss.
Noise Health
January 2025
Department of Otolaryngology, Head and Neck Surgery, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde 415000, Hunan, China.
Objective: In this study, the research team aimed to explore the therapeutic effectiveness of hyperbaric oxygen therapy (HBOT) for noise-induced hearing loss (NIHL), its influence on patient prognosis, and its impact on hearing to provide valuable clinical evidence.
Methods: Ninety-four patients with NIHL admitted to The First People's Hospital of Changde City, Hunan, China, from May 2021 to January 2023 were selected for this retrospective analysis. Among them, 43 were given conventional treatment (control group) and 51 were given HBOT (observation group).
Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragment covalently deposited on lymphoma cells.
Blood
January 2025
NIH, National Heart Lung Blood Institute, Bethesda, Maryland, United States.
Monoclonal antibodies (mAbs) improve survival of patients with mature B-cell malignancies. Fcγ-receptor dependent effector mechanisms kill tumor cells but can promote antigen loss through trogocytosis, contributing to treatment failures. Cell-bound mAbs trigger the complement cascade to deposit C3 activation fragments and lyse cells.
View Article and Find Full Text PDFChemotherapy-induced cellular senescence promotes stemness of aggressive B-cell non-Hodgkin's lymphoma via CCR7/ARHGAP18/IKBα signaling activation.
J Immunother Cancer
January 2025
Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonostic Infectious Disease, Huazhong University of Science and Technology, Wuhan, Hubei, China
Background: Resistance to existing therapies is a major cause of treatment failure in patients with refractory and relapsed B-cell non-Hodgkin's lymphoma (r/r B-NHL). Therapy-induced senescence (TIS) is one of the most important mechanisms of drug resistance.
Methods: This study used single-cell RNA sequencing to analyze doxorubicin-induced senescent B-NHL cells.
The Role of microRNA-155 as a Biomarker in Diffuse Large B-Cell Lymphoma.
Biomedicines
November 2024
Department of Hematology, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.
Diffuse Large B-cell Lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma (NHL). Despite the use of newer agents, such as polatuzumab vedotin, more than one-third of patients have ultimately relapsed or experienced refractory disease. MiRNAs are single-stranded, ~22-nucleotide-long RNAs that interact with their target RNA.
View Article and Find Full Text PDFThe Effect of Atorvastatin on Oncogenic miRNAs in Hematological Malignancies: A Central Study.
Biomolecules
December 2024
Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan.
The efficacy of statins as anti-cancer drugs has been demonstrated in several malignancies but has been poorly investigated in hematological malignancies (HM). By studying its effect on oncogenic miRNAs, we investigated the effect of statin therapy on HM patients. The data were used to identify enriched pathways that were altered due to statin treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!